ADCT vs AZN
ADCT: A commercial-stage oncology company pioneering antibody drug conjugates (ADCs) for patients with B-cell malignancies. AZN: AstraZeneca is a global, science-led biopharmaceutical company focused on transforming patient outcomes in oncology, rare diseases, and chronic conditions through a robust and diverse R&D pipeline.
Side-by-side fundamentals
| Metric | ADCT | AZN | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $1.59 | $158.78 | |
| Market cap | $203M | $181.5B | |
| P/E as of 2026-09-03 | n/a | 23.44 | |
| Net margin FY2025, SEC XBRL | -175.3% | +17.4% | AZN higher |
| Gross margin FY2025, SEC XBRL | n/a | +81.9% | |
| Operating margin FY2025, SEC XBRL | -149.3% | +23.4% | AZN higher |
| ROE FY2025, SEC XBRL | n/a | +21.0% | |
| ROA FY2025, SEC XBRL | -44.1% | +9.0% | AZN higher |
| Debt / equity as of 2026-09-03 | 9.01 | 0.64 | AZN lower |
| Revenue growth (YoY) as of 2026-09-03 | +4.4% | +8.6% | AZN higher |
| Revenue CAGR (3y) SEC XBRL | -27.1% | +9.8% | AZN higher |
| Dividend yield as of 2026-09-03 | n/a | +2.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 1.42 | 0.34 | |
| 1-year return as of 2026-10-08 close | -65.0% | -7.0% | AZN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.